CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.81, moving +2.61% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.72%. Elsewhere, the Dow ...

CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a ...

Synthego, a pioneering leader in genome engineering solutions, today announced that the Supreme Court of the United States has denied a petition for a writ of certiorari from Agilent Technologies, Inc ...

Crispr Therapeutics AG looks set for 2026 revenue inflection as Casgevy ramps; strong efficacy, undervalued shares, robust ...

CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

If you are wondering whether CRISPR Therapeutics at around US$45.75 is a bargain or a value trap, the answer depends on how you look at its valuation. The stock has returned 23.7% over the last year, ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.